Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Constantine Scordalakes

Obstetrics & Gynecology Newburgh, IN Medical Doctor

NPI 1437235645 CMS profile 201596

4199 Gateway Blvd, Suite 2300, Newburgh, IN 47630

Open in the dashboard

General payments

$22,364

454 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$247,316 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Constantine Scordalakes of Newburgh, IN is reported in the CMS Open Payments database as having received $22,364 across 454 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $247,316 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,240 58
2024 General $1,064 51
2023 General $2,836 69
2022 General $4,529 83
2021 General $2,135 86
2020 General $2,551 38
2019 General $7,009 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Constantine Scordalakes
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Constantine Scordalakes were reported at $2,240. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Constantine Scordalakes Obstetrics & Gynecology median Middle half National median
2019 $7,009 $172 $62–$391 $163
2020 $2,551 $94 $36–$222 $114
2021 $2,135 $136 $42–$369 $132
2022 $4,529 $160 $50–$433 $149
2023 $2,836 $169 $56–$423 $160
2024 $1,064 $152 $50–$371 $164
2025 $2,240 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Caldera Medical, Inc $5,418 5 payments
  2. Axonics Modulation Technologies, Inc. $3,236 22 payments
  3. AMAG Pharmaceuticals, Inc. $1,994 14 payments
  4. Intuitive Surgical, Inc. $1,590 6 payments
  5. Medtronic, Inc. $1,441 17 payments
  6. Agile Therapeutics, Inc. $1,233 7 payments
  7. AbbVie, Inc. $1,152 75 payments
  8. Coloplast Corp $847 5 payments
  9. Astellas Pharma US Inc $828 47 payments
  10. Sumitomo Pharma America, Inc. $446 24 payments
  11. Other $4,181 232 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,852 410 payments
  2. Consulting Fee $5,200 2 payments
  3. Travel and Lodging $5,135 23 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,920 2 payments
  5. Education $216 15 payments
  6. Gift $41 2 payments
Products named General payments · program years 2019–2025
  1. Desara $5,418 5 payments
  2. Vertessa $3,700 1 payment
  3. Bulkamid $3,236 22 payments
  4. Axonics $2,264 14 payments
  5. INTRAROSA $1,994 14 payments
  6. Da Vinci Surgical System $1,590 6 payments
  7. Twirla $1,120 1 payment
  8. Axonics r-SNM System $972 8 payments
  9. ALTIS $805 2 payments
  10. LO LOESTRIN FE $395 28 payments
  11. Other $7,608 446 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

693

Median for Obstetrics & Gynecology: 65

Drug cost

$79,096

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

41.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 48 $44,852
Myrbetriq Mirabegron Brand 15 $12,353
Methenamine Hippurate Generic 70 $4,624
Osphena Ospemifene Brand 11 $4,241
Estradiol Generic 71 $3,826
Trospium Chloride Er Trospium Chloride Brand 40 $3,715
Trospium Chloride Generic 24 $2,242
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 96 $797
Oxybutynin Chloride Er Oxybutynin Chloride Brand 29 $752
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 13 $444

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$74,488

Medicare's payments for the services billed

Medicare patients

355

Average age 72

Services billed

1,457

355 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 50%
Osteoporosis 23%
Diabetes 19%
Depression 19%
Chronic kidney disease 14%
Cancer 14%
Ischemic heart disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $94
  • PFIZER INC. $9
$103 — —
Veozah
  • Astellas Pharma US Inc $73
$73 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $41
$41 48 —
SLYND
  • Exeltis, USA Inc. $37
$37 — —
BOTOX
  • AbbVie, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

454 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record